# Profusa, Inc.: overview PFSA · Nasdaq · CIK 1859807 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/pfsa.md) · [Financials](/companies/pfsa/financials.md) · [Filings](/companies/pfsa/filings.md) · [Insiders](/companies/pfsa/insiders.md) Latest reported revenue: [$0](/filings/0001213900-26-044046.md) for Q4 FY2024, three months to 2024-12-31, from the 10-K filed Apr 15, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-044046). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [75.0](/filings/0001213900-25-112723.md) | [0.0 d](/filings/0001213900-26-044046.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1470.7%)](/filings/0001213900-25-112723.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | [(3329.3%)](/filings/0001213900-25-112723.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.29)](/filings/0001213900-25-112723.md) | not reported | [(105.09)](/filings/0001213900-26-057887.md) | [(9100.78)](/filings/0001213900-26-091696.md) | [(0.70)](/filings/0001213900-25-112723.md) | not reported | [(2.05)](/filings/0001213900-26-057887.md) | [(151.80)](/filings/0001213900-26-091696.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | [(2,581)](/filings/0001213900-26-057887.md) | [(2,705) d](/filings/0001213900-26-091696.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [0.1](/filings/0001213900-26-044046.md) | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [(4500.0%)](/filings/0001213900-26-044046.md) | not reported | | Net margin | % | not reported | not reported | [(9230.0%)](/filings/0001213900-26-044046.md) | not reported | | Diluted EPS | $ per share | [0.30](/filings/0001213900-24-016600.md) | [0.12](/filings/0001013762-25-004396.md) | [(357.14)](/filings/0001213900-26-044046.md) | [(107.01)](/filings/0001213900-26-044046.md) | | Free cash flow | $m | not reported | not reported | not reported | [(16.3)](/filings/0001213900-26-044046.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pfsa/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Ancora Advisors LLC](/funds/1446114.md) | 2026-06-30 | $167 | 33,458 | | Unchanged | ## Recent filings [All 323 filings](/companies/pfsa/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-15 | 06:10 ET | [8-K](/filings/0001213900-26-109558.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-109558 | | 2026-10-09 | 17:00 ET | [8-K](/filings/0001213900-26-108552.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001213900-26-108552 | | 2026-10-05 | 06:07 ET | [8-K](/filings/0001213900-26-106610.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001213900-26-106610 | | 2026-09-21 | 20:23 ET | [8-K](/filings/0001213900-26-101568.md) | 5.07 Shareholder vote results | 0001213900-26-101568 | | 2026-09-16 | 06:11 ET | [8-K](/filings/0001213900-26-100304.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001213900-26-100304 | | 2026-09-15 | 06:01 ET | [8-K](/filings/0001213900-26-099871.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-099871 | | 2026-09-01 | 08:15 ET | [8-K](/filings/0001213900-26-095984.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001213900-26-095984 | | 2026-08-31 | 08:54 ET | [8-K](/filings/0001213900-26-095405.md) | 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001213900-26-095405 | | 2026-08-28 | 16:30 ET | [DEF 14A](/filings/0001213900-26-095087.md) | Proxy statement, period 2026-09-18 | 0001213900-26-095087 | | 2026-08-21 | 16:05 ET | [8-K](/filings/0001213900-26-092597.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-092597 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-044046.md), filed Apr 15, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1859807 - Tickers: PFSA, NVACW - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:32 ET. No prices; not investment advice.